title: Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers.
abstract: Continuous hyperthermic peritoneal perfusion (CHPP) combined with administration of anticancer drugs was performed in eight colorectal cancer patients with peritoneal dissemination. An overall response rate of 50 percent was achieved in the eight patients. Two of three complete responders are long, recurrence-free survivors for 15 and 30 months. The two-year survival has been achieved in 18.8 percent of the patients receiving CHPP, and this rate is significantly higher than the rates in P2 and P3 patients who did not receive CHPP. The complications of CHPP with administration of anticancer drugs were mild bone marrow suppression in two (25 percent) of the eight patients and also a mild grade of renal dysfunction in one (12.5 percent), though not lethal. The results suggest that the combination of CHPP with the administration of anticancer drugs is a safe and effective therapy for peritoneal dissemination of colorectal cancers.
authors.affiliation: Department of Surgery II, School of Medicine, Kanazawa University, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Yamaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukioka
authors.forename: S
authors.initials: S
authors.lastname: Fushida
authors.forename: Y
authors.initials: Y
authors.lastname: Kurosaka
authors.forename: M
authors.initials: M
authors.lastname: Kanno
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: K
authors.initials: K
authors.lastname: Miwa
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D016019:Survival Analysis
chemical_list: D009944:Organoplatinum Compounds; C055423:didimethylsulfoxide dichloroplatinum(II); D016685:Mitomycin